Format

Send to

Choose Destination
PLoS Pathog. 2014 Apr 10;10(4):e1004060. doi: 10.1371/journal.ppat.1004060. eCollection 2014 Apr.

A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection.

Author information

1
Department of Infectious Diseases, Genentech, South San Francisco, California, United States of America.
2
Department of Translational Immunology, Genentech, South San Francisco, California, United States of America.
3
Department of Antibody Engineering, Genentech, South San Francisco, California, United States of America.
4
Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, California, United States of America.
5
Department of Biomedical Imaging, Genentech, South San Francisco, California, United States of America.
6
Department of Clinical Pharmacology, Genentech, South San Francisco, California, United States of America.
7
Department of Biostatistics, Genentech, South San Francisco, California, United States of America.

Abstract

Human cytomegalovirus (HCMV) is the most common cause of congenital virus infection. Congenital HCMV infection occurs in 0.2-1% of all births, and causes birth defects and developmental abnormalities, including sensorineural hearing loss and developmental delay. Several key studies have established the guinea pig as a tractable model for the study of congenital HCMV infection and have shown that polyclonal antibodies can be protective. In this study, we demonstrate that an anti-guinea pig CMV (GPCMV) glycoprotein H/glycoprotein L neutralizing monoclonal antibody protects against fetal infection and loss in the guinea pig. Furthermore, we have delineated the kinetics of GPCMV congenital infection, from maternal infection (salivary glands, seroconversion, placenta) to fetal infection (fetus and amniotic fluid). Our studies support the hypothesis that a neutralizing monoclonal antibody targeting an envelope GPCMV glycoprotein can protect the fetus from infection and may shed light on the therapeutic intervention of HCMV congenital infection in humans.

PMID:
24722349
PMCID:
PMC3983071
DOI:
10.1371/journal.ppat.1004060
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center